Novartis

Novartis AG is a holding company, which engages in the development, manufacture, and marketing of healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment researches, develops, manufactures, distributes and sells patented pharmaceuticals, and is composed of two business units: Novartis Oncology and Novartis Pharmaceuticals. The Sandoz segment develops, manufactures and markets finished dosage form medicines as well as intermediary products, including active pharmaceutical ingredients. The Corporate segment refers to group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novartis AG is a holding company, which engages in the business of developing, manufacturing, and marketing healthcare products. It operates through the following segments: Innovative Medicines, Sandoz, and Corporate. The Innovative Medicines segment includes researching, distributing and selling patented pharmaceuticals. The Sandoz segment focuses on marketing finished dosage form medicines and intermediary products including active pharmaceutical ingredients. The Corporate segment is involved in group management and central services. The company was founded on February 29, 1996 and is headquartered in Basel, Switzerland.

Basel, June 3, 2021 — Novartis today announced that results of the Phase III VISION study evaluating 177Lu-PSMA-617, a targeted radioligand therapy, plus best standard of care (SOC) demonstrated significant improvement in overall survival (OS) compared to SOC alone, in patients with progressive PSMA-positive metastatic castration-resistant prostate cancer (mCRPC)1. The difference in OS between study arms was statistically significant (one-sided p

Novartis 177Lu-PSMA-617 significantly improves overall survival and radiographic progression-free survival for men with metastatic castration-resistant prostate cancer in Phase III VISION study

Alnylam Pharmaceuticals

Intellia Therapeutics

Pfizer

Regeneron Pharmaceuticals

Here's one genetics play that you might want to put on your radar.

This Genetics Stock Could Have a Bright Future

Basel, June 2, 2021 — Novartis today announced robust data from the primary analysis of the pivotal Phase II ELARA trial of Kymriah® (tisagenlecleucel) in patients with relapsed or refractory (r/r) follicular lymphoma (FL)1. Data will be presented as an oral presentation during the 2021 Annual American Society of Clinical Oncology (ASCO) Virtual Scientific Meeting (Abstract #7508; oral presentation: Monday, June 7, 10:30 AM CDT).

Novartis Kymriah® pivotal trial demonstrates strong response rates and a remarkable safety profile in relapsed or refractory follicular lymphoma

Novartis AG (NYSE: NVS) said that the Phase 3 JUNIPERA study met its primary endpoint, with Cosentyx (secukinumab) showing a significantly longer time to worsening of symptoms compared to placebo in pediatric patients with two subtypes of juvenile idiopathic arthritis (JIA). The data will be presented at the EULAR 2021 Annual European Congress of Rheumatology.

Novartis's Late-stage Study On Cosentyx Hits Primary Endpoint Goal In Juvenile Idiopathic Arthritis

The FDA has approved Novartis AG's (NYSE: NVS) Cosentyx (secukinumab) to treat moderate to severe plaque psoriasis in pediatric patients six years and older and are candidates for systemic therapy or phototherapy. The approved dosing is 75 mg or 150 mg depending on the child's weight at the time of dosing and is administered by subcutaneous injection every four weeks after an initial loading regimen.

Novartis's Cosentyx Wins FDA Approval For Psoriasis In Pediatric Patients

Basel, June 2, 2021 — Novartis, a leader in rheumatology and immuno-dermatology, today announced 2-year positive results from the Phase III JUNIPERA study, demonstrating that Cosentyx® (secukinumab) significantly delayed time to flare vs placebo (P

Novartis presents positive Phase III results from JUNIPERA study supporting Cosentyx® as a potential treatment in a JIA population at EULAR 2021

Novartis AG (NYSE: NVS) has announced that three Phase 3 studies evaluating Beovu (brolucizumab) in patients with retinal diseases will be terminated early after more frequent dosing intervals were associated with higher rates of intraocular inflammation. The MERLIN study and the RAPTOR and RAVEN studies will be stopped.

Novartis Terminates Three Beovu Studies in Ocular Disorders Citing Patient Safety

AbbVie

Algonquin Power & Utilities

British American Tobacco

Cardinal Health

Canadian Imperial Bank of Commerce

Canadian Natural Resources

Chevron

Enbridge

Pembina Pipeline

Sanofi

AT&T

TC Energy

Kiplinger "insights for investors" online, first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 5/25/21 revealed 13 yields ripe for picking. These International “Dividend Aristocrats,” have raised dividends at least five straight years (Canadian) 10 years (European Union) or 25 years (U.S. companies).

The 91 'Best Dividend Stocks On Earth' For June

CureVac B.V

Repligen

Novartis (NVS) initiates study for investigating its novel DARPin therapeutic candidate, ensovibep (MP0420), for the treatment of COVID-19, in collaboration with Molecular Partners.

Novartis (NVS) & Molecular Partners Initiate Study for COVID-19

Novartis AG (NYSE: NVS) along with Molecular Partners AG (OTC: MLLCF) is kicking off a Phase 2/3 EMPATHY study of DARPin therapeutic candidate, ensovibep (MP0420), to treat COVID-19. The program is investigating the safety and efficacy of ensovibep in patients with COVID-19, who are in the early stages of infection, to prevent worsening symptoms and hospitalization.

Novartis, Molecular Partners Initiate Global Trial For COVID-19 Treatment

EMPATHY global multi-center Phase 2 - 3 study, recruiting patients with COVID-19 infection, aiming to prevent worsening symptoms and hospitalization The study plans to enroll 2100 patients, with 400 patients to be enrolled into Phase 2, followed by 1700 patients in Phase 3 Novartis has been granted an option from Molecular Partners to in-license global rights of ensovibep and MP0423 - DARPin® antiviral therapeutic candidates that are undergoing testing to target SARS-CoV-2 spike protein DARPin® therapeutics well suited for a pandemic setting due to multi-specific target binding, long half-life for sustained activity and highly scalable production, compared to monoclonal antibodies ZURICH-SCHLIEREN, SWITZERLAND / ACCESSWIRE / May 27, 2021 / Molecular Partners AG (SIX:MOLN) and Novartis announced today the start of the clinical trial EMPATHY, a Phase 2 and 3 study, to explore the use of its novel DARPin® therapeutic candidate ensovibep (MP0420) for the treatment of COVID-19. Novartis will conduct the clinical trial program for ensovibep, with Molecular Partners as sponsor of the studies.

Novartis and Molecular Partners announce start of EMPATHY clinical trial for ensovibep for the treatment of COVID-19

Basel, May 19, 2021 — Novartis will present new data from its portfolio of approved and investigational targeted, radioligand, cell and gene and immunotherapies at the upcoming 2021 American Society of Clinical Oncology (ASCO) Annual Meeting and the 2021 European Hematology Association (EHA) Virtual Congress. More than 110 abstracts, including Novartis-sponsored and investigator-initiated trials, will be presented at the meetings.

Novartis to unveil new data at ASCO and EHA from its robust portfolio, including overall survival in prostate and breast cancer

Novartis AG (NVS) Presents at Cardiovascular Update Broker Conference Call - (Transcript)

Amgen

The Supreme Court turned away a petition from Sandoz seeking to challenge two Amgen Inc (NASDAQ: AMGN) patents related to rheumatoid arthritis drug Enbrel, thus blocking Novartis AG's (NYSE: NVS) Sandoz from selling a biosimilar of the drug in the U.S. until 2029. The justices turned away Novartis subsidiary Sandoz Inc's appeal of a lower court decision that upheld the validity of the patents.

Supreme Court Rebuffs Novartis Appeal Over Amgen's Arthritis Drug Enbrel: Report

Novartis AG (NYSE: NVS) revealed details on Phase 3 PARADISE-MI trial evaluating Entresto (sacubitril/valsartan) compared with ramipril in a contemporary acute myocardial infarction (AMI) population. Data were presented at the American College of Cardiology's virtual Scientific Session.

Novartis' Entresto Misses Primary Endpoint In Study After Heart Attacks

The stock price of Novartis AG (NYSE: NVS) increased by 1.01% as it went from $85.24 to $86.10 pre-market. This is why it happened.

NVS Stock: From $85.24 To $86.10 (1.01% Increase) Pre-Market Explanation

Novartis AG (NYSE: NVS) has reported that its Beovu (brolucizumab) drug met primary endpoints in Phase 3 KESTREL and KITE trials conducted in diabetic macular edema (DME) patients. According to one-year data, 6mg Beovu showed non-inferiority in change in best-corrected visual acuity from baseline compared to 2mg Regeneron Pharmaceuticals Inc's (NASDAQ: REGN) Eylea (aflibercept).

Novartis' Beovu Non-Inferior To Aflibercept In Phase 3 Diabetic Macular Edema Study

Basel, May 1, 2021 — Novartis today announced positive one-year results of the Phase III KESTREL and KITE* studies, evaluating the efficacy and safety of Beovu® (brolucizumab) 6 mg in diabetic macular edema (DME). Both studies met their primary endpoints of non-inferiority in change in best corrected visual acuity (BCVA) from baseline for Beovu 6 mg versus aflibercept 2 mg at year one1. In KESTREL, patients on Beovu 6 mg gained a mean of 9.2 letters versus 10.5 letters for patients on aflibercept 2 mg1. In KITE, patients on Beovu 6 mg gained a mean of 10.6 letters versus 9.4 letters for patients on aflibercept 2 mg1. These results will be presented at the Association for Research in Vision and Ophthalmology (ARVO) 2021 Annual Meeting.

Novartis Phase III Beovu® data show potential for fluid resolution in more diabetic macular edema patients with fewer injections versus aflibercept

The Eaton Vance Worldwide Health Sciences Fund (Trades, Portfolio) sold shares of the following stocks during the first quarter of 2021, which ended on March 31.

The Eaton Vance Fund sells Novartis, Pfizer

Coca-Cola

Realty Income Corp

Unilever

Kiplinger "insights for investors" online first offered this list of 91 "Top Dividend Stocks From Around The World" July 13, 2020. Data updated 4/26/21 flagged 13 yields ripe with upside. These International “Dividend Aristocrats” have raised dividends at least five straight years (Canadian), 10 years (European Union), or 25 years (U.S. companies).

Update: 91 'Top Dividend Stocks On Earth' For May

Bristol-Myers

Gilead Sciences

GlaxoSmithKline

Johnson & Johnson

Merck

So, which pharmaceutical stocks should be on your radar, if dividends are a top priority? Consider these seven compelling opportunities.

7 Pharmaceutical Stocks With Dividends in Hand

Novartis continues to be hurt by the pandemic, with damage to the ophthalmology and oncology markets continuing to drag on overall performance. Sandoz remains a troubled area, with a weak flu season in addition to pricing pressures accentuating problems with the business line.

Novartis Continues To Hurt From Ophthalmology And Oncology, Sandoz Drags As Well

Novartis AG's (NVS) CEO Vas Narasimhan on Q1 2021 Results - Earnings Call Transcript

Novartis (NVS) reports lower-than-expected first-quarter results, as the pandemic continues to negatively impact sales.

Novartis (NVS) Q1 Earnings & Sales Miss Estimates on COVID-19 Woes

Why Novartis Missed Wall Street Q1 Estimates

News for Novartis Stock (NVS)